 |
94 Diseases |  |
6 Trials |
|
6 Trials |  |
1432 News |  |
| «12...3456789101112131415 |
- | Trial completion: Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (clinicaltrials.gov) - Jan 23, 2013
P3, N=451, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed
- stavudine / Generic mfg., zidovudine / Generic mfg.
Enrollment open, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - Dec 16, 2012
P4, N=70, Recruiting, Sponsor: Tufts University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- zidovudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
New P2 trial, Combination therapy: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects (clinicaltrials.gov) - Nov 28, 2012
P2, N=0, Withdrawn, Sponsor: RFS Pharma, LLC
- | tenofovir disoproxil fumarate / Generic mfg., zidovudine / Generic mfg.
New P2a trial, Combination therapy: A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. (clinicaltrials.gov) - Nov 27, 2012
P2a, N=45, Active, not recruiting, Sponsor: RFS Pharma, LLC
- Enrollment change: Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth (clinicaltrials.gov) - Nov 4, 2012
P2, N=175, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=300 --> 175
- Trial completion: Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth (clinicaltrials.gov) - Nov 4, 2012
P2, N=175, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=300 --> 175 Active, not recruiting --> Completed
- didanosine / Generic mfg., zidovudine / Generic mfg.
Trial completion: A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection (clinicaltrials.gov) - Oct 30, 2012
P1, N=85, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- zidovudine / Generic mfg.
Enrollment change: Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma (clinicaltrials.gov) - Oct 15, 2012
P=N/A, N=13, Active, not recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Completed N=35 --> 13
- | stavudine / Generic mfg., zidovudine / Generic mfg.
New P4 trial, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - Sep 24, 2012
P4, N=70, Recruiting, Sponsor: Tufts University
- Enrollment change: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
N=35 --> 13 N=42 --> 11
- Trial completion: Sex, Aging and Antiretroviral Pharmacokinetics (clinicaltrials.gov) - Sep 17, 2012
P=N/A, N=11, Completed, Sponsor: Kristine Patterson, MD
N=42 --> 11 Recruiting --> Completed
- efavirenz / Generic mfg., zidovudine / Generic mfg., lamivudine / Generic mfg.
Enrollment change: COAT: Cryptococcal Optimal ART Timing Trial (clinicaltrials.gov) - Jun 24, 2012
P4, N=177, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Completed N=500 --> 177
- stavudine / Generic mfg., zidovudine / Generic mfg.
Enrollment change, Adverse events: Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine (clinicaltrials.gov) - May 14, 2012
P2, N=3, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
N=500 --> 177 N=20 --> 3
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial completion, Adverse events: Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine (clinicaltrials.gov) - May 14, 2012
P2, N=3, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
N=20 --> 3 Recruiting --> Completed
- Invirase (saquinavir) / Roche
Enrollment change, IO biomarker: A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy (clinicaltrials.gov) - Apr 19, 2012
P2, N=6, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=254 --> 6
- zidovudine / Generic mfg.
Trial completion: A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy (clinicaltrials.gov) - Mar 28, 2012
P=N/A, N=400, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=254 --> 6 Active, not recruiting --> Completed
- zidovudine / Generic mfg.
Trial withdrawal: A Study of Zidovudine in HIV-Infected Patients With Kidney Problems (clinicaltrials.gov) - Mar 14, 2012
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Terminated --> Withdrawn
- zidovudine / Generic mfg.
Enrollment change: A Study of Zidovudine in HIV-Infected Patients With Kidney Problems (clinicaltrials.gov) - Mar 14, 2012
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Terminated --> Withdrawn N=30 --> 0
- zidovudine / Generic mfg.
Trial completion: A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women (clinicaltrials.gov) - Mar 14, 2012
P1, N=36, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=30 --> 0 Active, not recruiting --> Completed
- || zidovudine / Generic mfg.
New P2/3 trial: Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-na (clinicaltrials.gov) - Feb 21, 2012
P2/3, N=136, Recruiting, Sponsor: University Hospital, Geneva
- | Trial completion: Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) (clinicaltrials.gov) - Feb 13, 2012
P3, N=120, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- zidovudine / Generic mfg., abacavir / Generic mfg.
Trial completion: A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women (clinicaltrials.gov) - Feb 13, 2012
P1, N=60, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| darunavir/ritonavir / Generic mfg.
New P3 trial: Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r) (clinicaltrials.gov) - Jan 23, 2012
P3, N=316, Completed, Sponsor: Janssen-Cilag G.m.b.H
- zidovudine / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change: Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=529, Completed, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed N=372 --> 529
- zidovudine / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion: SWOG 9320: SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma (clinicaltrials.gov) - Jan 11, 2012
P2, N=52, Completed, Sponsor: Southwest Oncology Group
N=372 --> 529 Active, not recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
New P2 trial: Tocilizumab for KSHV-Associated Multicentric Castleman Disease (clinicaltrials.gov) - Sep 25, 2011
P2, N=17, Recruiting, Sponsor: National Cancer Institute (NCI)